12 research outputs found
Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in Non-small Cell Lung Cancer
No full textBACKGROUND:This study was designed to investigate potential molecules that predict chemosensitivity to pemetrexed (Alimta®) in surgically resected non-small cell lung cancer (NSCLC). / MATERIALS AND METHODS:Chemosensitivity to ALM and other drugs was assessed by succinate dehydrogenase inhibition (SDI) test in 69 NSCLC samples (55 adenocarcinomas, and 14 squamous cell carcinomas). The mRNA expression levels of Alimta®-target enzymes [thymidylate synthase (TYMS); dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT)], Alimta®-metabolizing enzymes [γ-glutamyl hydrase (GGH) and folylpolyglutamate synthase] and an Alimta® transporter [reduce folate carrier (RFC)] were measured and examined for potential correlations to chemosensitivity. / RESULTS:The squamous cell carcinoma samples showed higher TYMS expression and lower RFC expression than did the adenocarcinoma samples. In the adenocarcinoma sample analyses, GGH expression was inversely correlated to sensitivity. / CONCLUSION:The histology-dependent differences in chemosensitivity to Alimta® may be attributed to the histology-dependent differences in TYMS and RFC expression. In adenocarcinomas, GGH potentially represents a marker for chemosensitivity to Alimta®
Re-biopsy in advanced non-small cell lung cancer patients after the development of 3rd generation EGFR-TKI and new targeted therapies.
No full textPrognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR
No full textApplication of Continuous Negative Pressure Irrigation and Negative Pressure Fixation to Treat a Bronchopleural Fistula with Thoracic Empyema
No full textSecondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib
No full textExperience with Erlotinib in Lung Adenocarcinoma Harboring a Coexisting KIF5B-RET Fusion Gene and EGFR Mutation: Report of a Rare Case
No full textVerification of the Newly Proposed T Category (Seventh Edition of the Tumor, Node, and Metastasis Classification) from a Clinicopathological Viewpoint in Non-small Cell Lung Cancer—Special Reference to Tumor Size
No full textConcurrent Chemoradiotherapy for Patients With Postoperative Recurrence of Surgically Resected Non–Small-Cell Lung Cancer
No full textBioKnife, a uPA Activity-dependent Oncolytic Sendai Virus, Eliminates Pleural Spread of Malignant Mesothelioma via Simultaneous Stimulation of uPA Expression
No full textFeasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer
No full text
